266354
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 11
- fusion
- other ZFTA
- e1_e2
- E2
- umap1_2d
- -5.081436366
- umap2_2d
- 1.163303499
- umap1_3d
- -0.821509272
- umap2_3d
- 3.259672661
- umap3_3d
- -0.077417854
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.480
- MYC_TARGETS_V1+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- MTORC1_SIGNALING+0.430
- MYC_TARGETS_V2+0.420
- TNFA_SIGNALING_VIA_NFKB+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.410
- IL6_JAK_STAT3_SIGNALING+0.350
- APOPTOSIS+0.320
Top 10 suppressed
- BILE_ACID_METABOLISM-0.200
- WNT_BETA_CATENIN_SIGNALING-0.190
- SPERMATOGENESIS-0.160
- KRAS_SIGNALING_DN-0.120
- FATTY_ACID_METABOLISM-0.100
- ADIPOGENESIS-0.090
- APICAL_JUNCTION-0.070
- XENOBIOTIC_METABOLISM-0.040
- PEROXISOME-0.030
- HEME_METABOLISM-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934835 | — | — | 0.916 |
| 2 | BS_F6V1Y4QS | Glial-neuronal tumor NOS | — | 0.913 |
| 3 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.912 |
| 4 | MDT-AP-0309 | Med | Medulloblastoma | 0.901 |
| 5 | SRR934730 | — | — | 0.899 |
| 6 | SRR12696771 | — | — | 0.898 |
| 7 | SRR934837 | — | — | 0.896 |
| 8 | SRR934839 | — | — | 0.894 |
| 9 | SRR934926 | — | — | 0.894 |
| 10 | SRR934965 | — | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.410 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |